Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 8/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.35 |
| ▸ | DPP4 | P27487 | 5/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179330 | 1.00 | GAA (0.36) | GAAHPGDDPP7CA12CA1 | |
| SCHEMBL30443171 | 0.98 | CHRM2 (0.37) | GAAHPGDDPP7CA12CA1 | |
| SCHEMBL21773024 | 0.93 | — | — | |
| SCHEMBL19408961 | 0.93 | — | — | |
| SCHEMBL3488662 | 0.93 | — | — | |
| Glycine SCHEMBL4955985 | 0.90 | DPP4 (0.39) | DPP7CHRM2CHRM4CHRM5CHRM1 | |
| Alanine SCHEMBL4955495 | 0.87 | DPP4 (0.44) | DPP7CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL21296547 | 0.83 | — | — | |
| Serine SCHEMBL4955395 | 0.83 | DPP7 (0.40) | DPP7CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4002060 | 0.82 | GAA (0.36) | GAAHPGDDPP7CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 489 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439226-B2 | Serine protease inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-10-21 | — | — | US | claimed |
| EP-1761554-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | Biosource Pharm, Inc. (US) | 2007-03-14 | — | — | EP | claimed |
| WO-2006083317-A2 | PEPTIDE ANTIBIOTICS AND METHODS FOR MAKING SAME | BIOSOURCE PHARM, INC. (US) | 2006-08-10 | — | — | WO | claimed |
| WO-2006043933-A1 | SERINE PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-04-27 | — | — | WO | claimed |
| US-20050130883-A1 | Serine protease inhibitors | THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2005-06-16 | — | — | US | claimed |
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | UNIV MICHIGAN (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4680108-A1 | PEPTIDE MULTIMER PRODUCTS AND METHODS | The Regents of The University of Michigan (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4658644-A1 | 2-(PYRIDAZIN-3-YL)-5-(TRIFLUOROMETHYL)PHENOLS AS NLRP3 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2025-12-10 | — | — | EP | disclosed |
| US-20250263685-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | GENZYME CORPORATION | 2025-08-21 | — | — | US | disclosed |
| US-20250263439-A1 | HETERODIMERIC PEPTIDE REAGENTS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-08-21 | — | — | US | disclosed |
| EP-3660040-B1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4565333-A2 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | Regents of the University of Michigan (US) | 2025-06-11 | — | — | EP | disclosed |
| WO-2006043933-A1 | SERINE PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2005060949-A2 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050148515-A1 | Peptidomimetics; determining ability to bind growth hormone secretagogue; ghrelin agonists; appetite stimulation; dietetics | IPSEN PHARMA S.A.S. (FR) | 2005-07-07 | — | — | US | disclosed |
| US-20050130883-A1 | Serine protease inhibitors | THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2005-06-16 | — | — | US | disclosed |
| US-6806273-B1 | 5-THIO-THIAZOLO(4,5-D)PYRIMIDIN-7-YL DERIVATIVES; CHEMOKINE RECEPTOR (ESPECIALLY CXCR2) ACTIVITY MODULATORS | ASTRAZENECA AB (SE) | 2004-10-19 | — | — | US | disclosed |
| US-20040059088-A1 | Short amphipathic peptides with activity against bacteria and intracellular pathogens | MCLAUGHLIN MARK L (US) | 2004-03-25 | — | — | US | disclosed |
| US-6566334-B1 | For therapy of bacterial infection | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2003-05-20 | — | — | US | disclosed |
| CN-1177299-A | Certain 1, 4, 5 -tri- substituted imidazole compounds useful as cytokine | SMITHKLINE BEECHAM CORP (US) | 1998-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055150-A1 | GRAIL-1 PEPTIDE PRODUCTS AND METHODS | TP53, TP53BP1, DDIT3 | GAA 3459/4885HPGD 4316/4885DPP7 4473/4885 |
| US-20050148515-A1 | Peptidomimetics; determining ability to bind growth hormone secretagogue; ghrelin agonists; appetite stimulation; dietetics | GIPR, GHSR, GHRHR | GAA 4561/4885HPGD 2609/4885DPP7 120/4885 |
| US-20250263439-A1 | HETERODIMERIC PEPTIDE REAGENTS AND METHODS | ERBB2, EGFR, ERBB3 | GAA 2999/4885HPGD 2739/4885DPP7 2248/4885 |
| US-20040059088-A1 | Short amphipathic peptides with activity against bacteria and intracellular pathogens | VIP, MDK, HM13 | GAA 1946/4885HPGD 3821/4885DPP7 249/4885 |
| US-20250263685-A1 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF | MAN2B1, MAN1B1, GAA | GAA 3/4885HPGD 3804/4885DPP7 692/4885 |
| US-20050130883-A1 | Serine protease inhibitors | PRSS1, TASP1, METAP1 | GAA 1191/4885HPGD 2388/4885DPP7 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.